跳至主要内容
临床试验/NCT00613301
NCT00613301已完成不适用

Pramipexole Special Survey on Patients Without Concomitant Use of L-Dopa

Boehringer Ingelheim119 个研究点 分布在 1 个国家目标入组 416 人开始时间: 2004年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
416
试验地点
119
主要终点
Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events

研究概览

简要总结

The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with Parkinson's disease who do not receive L-Dopa supplementation

排除标准

  • Patients should have been treated according to the Japanese insert slip

结局指标

主要结局

Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events

时间窗: during 36 months

The aim of this Post Marketing Surveillance (PMS) was to obtain safety data in Parkinson's disease (PD) patients without concomitant use of levodopa for 3 years.

次要结局

  • Clinical Global Impression of Improvement(after 36 months treatment)
  • Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score(Baseline and at 36 months (or at the time of discontinuation))
  • Change From Baseline in Modified Hoehn & Yahr Rating Scale(Baseline and at 36 months (or at the time of discontinuation))

研究者

申办方类型
Industry

研究点 (119)

Loading locations...

相似试验

Special Survey on Parkinson's Disease (PD) Patients... | 临床试验